Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen. Chronic infection with hepatitis C virus (HCV) represents a serious health issue...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2011-09, Vol.365 (11), p.1014-1024 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1024 |
|---|---|
| container_issue | 11 |
| container_start_page | 1014 |
| container_title | The New England journal of medicine |
| container_volume | 365 |
| creator | Sherman, Kenneth E Flamm, Steven L Afdhal, Nezam H Nelson, David R Sulkowski, Mark S Everson, Gregory T Fried, Michael W Adler, Michael Reesink, Hendrik W Martin, Marie Sankoh, Abdul J Adda, Nathalie Kauffman, Robert S George, Shelley Wright, Christopher I Poordad, Fred |
| description | In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen.
Chronic infection with hepatitis C virus (HCV) represents a serious health issue for nearly 200 million infected persons worldwide.
1
Achievement of a sustained virologic response may be associated with improved long-term clinical outcomes, including increased survival.
2
,
3
In patients infected with HCV genotype 1, 48 weeks of treatment with peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to 50%.
4
,
5
Telaprevir administered in combination with peginterferon and ribavirin has led to high rates of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV genotype 1 infection, who have not . . . |
| doi_str_mv | 10.1056/NEJMoa1014463 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3809077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2455752991</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-9db28b5f527c3ab0b045adfcdf06b2369a63cb571fda69649fef370b78702d2f3</originalsourceid><addsrcrecordid>eNp1kM1LHTEUxYNU9Gm7dFuGgstpbyaZZLIRysOqxY9SXrsNSSapebxJxmRG6H9vxKfWRe8mcPPjnHMPQkcYPmNo2Zfr0-9XUWHAlDKygxa4JaSmFNg7tABouppyQfbRQc5rKIOp2EP7DRaYMSIW6MdPm8cYsq3PZt_bvlrZjRqTvfepWsZB-6AmH0O1SlZNgw1T5WKqzu1Y1pPP1bL67dOcq4vgrHkk36NdpzbZfti-h-jXt9PV8ry-vDm7WH69rA3lZKpFr5tOt65tuCFKgwbaqt6Z3gHTDWFCMWJ0y7HrFROMCmcd4aB5x6HpG0cO0cmT7jjrwfamREtqI8fkB5X-yqi8fPsT_K38E-8l6UAA50Xg01YgxbvZ5kmu45xCySw7AdBhQdsC1U-QSTHnZN2LAQb52L9803_hP_6b6oV-LrwAx1tAZaM2LqlgfH7limc5sX3lhiHLYNfDfwwfAJmtmo8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>890081945</pqid></control><display><type>article</type><title>Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Sherman, Kenneth E ; Flamm, Steven L ; Afdhal, Nezam H ; Nelson, David R ; Sulkowski, Mark S ; Everson, Gregory T ; Fried, Michael W ; Adler, Michael ; Reesink, Hendrik W ; Martin, Marie ; Sankoh, Abdul J ; Adda, Nathalie ; Kauffman, Robert S ; George, Shelley ; Wright, Christopher I ; Poordad, Fred</creator><creatorcontrib>Sherman, Kenneth E ; Flamm, Steven L ; Afdhal, Nezam H ; Nelson, David R ; Sulkowski, Mark S ; Everson, Gregory T ; Fried, Michael W ; Adler, Michael ; Reesink, Hendrik W ; Martin, Marie ; Sankoh, Abdul J ; Adda, Nathalie ; Kauffman, Robert S ; George, Shelley ; Wright, Christopher I ; Poordad, Fred ; ILLUMINATE Study Team</creatorcontrib><description>In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen.
Chronic infection with hepatitis C virus (HCV) represents a serious health issue for nearly 200 million infected persons worldwide.
1
Achievement of a sustained virologic response may be associated with improved long-term clinical outcomes, including increased survival.
2
,
3
In patients infected with HCV genotype 1, 48 weeks of treatment with peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to 50%.
4
,
5
Telaprevir administered in combination with peginterferon and ribavirin has led to high rates of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV genotype 1 infection, who have not . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa1014463</identifier><identifier>PMID: 21916639</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Waltham, MA: Massachusetts Medical Society</publisher><subject>Adult ; Aged ; Anemia ; Anemia - chemically induced ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral drugs ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Biological and medical sciences ; Biopsy ; Chronic infection ; Drug Therapy, Combination ; Exanthema - chemically induced ; Female ; General aspects ; Genotype & phenotype ; Genotypes ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C - drug therapy ; Hepatitis C - virology ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Interferon ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Oligopeptides - adverse effects ; Oligopeptides - therapeutic use ; Patients ; Pharmaceuticals ; Pharmacology. Drug treatments ; Polyethylene Glycols - therapeutic use ; Recombinant Proteins ; Ribavirin ; Ribavirin - therapeutic use ; Ribonucleic acid ; RNA ; Technical communication ; Viral diseases ; Viral hepatitis ; Young Adult</subject><ispartof>The New England journal of medicine, 2011-09, Vol.365 (11), p.1014-1024</ispartof><rights>Copyright © 2011 Massachusetts Medical Society. All rights reserved.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Massachusetts Medical Society. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-9db28b5f527c3ab0b045adfcdf06b2369a63cb571fda69649fef370b78702d2f3</citedby><cites>FETCH-LOGICAL-c473t-9db28b5f527c3ab0b045adfcdf06b2369a63cb571fda69649fef370b78702d2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa1014463$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/890081945?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,777,781,882,2746,2747,26084,27905,27906,52363,54045,64364,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24537875$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21916639$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sherman, Kenneth E</creatorcontrib><creatorcontrib>Flamm, Steven L</creatorcontrib><creatorcontrib>Afdhal, Nezam H</creatorcontrib><creatorcontrib>Nelson, David R</creatorcontrib><creatorcontrib>Sulkowski, Mark S</creatorcontrib><creatorcontrib>Everson, Gregory T</creatorcontrib><creatorcontrib>Fried, Michael W</creatorcontrib><creatorcontrib>Adler, Michael</creatorcontrib><creatorcontrib>Reesink, Hendrik W</creatorcontrib><creatorcontrib>Martin, Marie</creatorcontrib><creatorcontrib>Sankoh, Abdul J</creatorcontrib><creatorcontrib>Adda, Nathalie</creatorcontrib><creatorcontrib>Kauffman, Robert S</creatorcontrib><creatorcontrib>George, Shelley</creatorcontrib><creatorcontrib>Wright, Christopher I</creatorcontrib><creatorcontrib>Poordad, Fred</creatorcontrib><creatorcontrib>ILLUMINATE Study Team</creatorcontrib><title>Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen.
Chronic infection with hepatitis C virus (HCV) represents a serious health issue for nearly 200 million infected persons worldwide.
1
Achievement of a sustained virologic response may be associated with improved long-term clinical outcomes, including increased survival.
2
,
3
In patients infected with HCV genotype 1, 48 weeks of treatment with peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to 50%.
4
,
5
Telaprevir administered in combination with peginterferon and ribavirin has led to high rates of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV genotype 1 infection, who have not . . .</description><subject>Adult</subject><subject>Aged</subject><subject>Anemia</subject><subject>Anemia - chemically induced</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral drugs</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Chronic infection</subject><subject>Drug Therapy, Combination</subject><subject>Exanthema - chemically induced</subject><subject>Female</subject><subject>General aspects</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oligopeptides - adverse effects</subject><subject>Oligopeptides - therapeutic use</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Recombinant Proteins</subject><subject>Ribavirin</subject><subject>Ribavirin - therapeutic use</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Technical communication</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Young Adult</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kM1LHTEUxYNU9Gm7dFuGgstpbyaZZLIRysOqxY9SXrsNSSapebxJxmRG6H9vxKfWRe8mcPPjnHMPQkcYPmNo2Zfr0-9XUWHAlDKygxa4JaSmFNg7tABouppyQfbRQc5rKIOp2EP7DRaYMSIW6MdPm8cYsq3PZt_bvlrZjRqTvfepWsZB-6AmH0O1SlZNgw1T5WKqzu1Y1pPP1bL67dOcq4vgrHkk36NdpzbZfti-h-jXt9PV8ry-vDm7WH69rA3lZKpFr5tOt65tuCFKgwbaqt6Z3gHTDWFCMWJ0y7HrFROMCmcd4aB5x6HpG0cO0cmT7jjrwfamREtqI8fkB5X-yqi8fPsT_K38E-8l6UAA50Xg01YgxbvZ5kmu45xCySw7AdBhQdsC1U-QSTHnZN2LAQb52L9803_hP_6b6oV-LrwAx1tAZaM2LqlgfH7limc5sX3lhiHLYNfDfwwfAJmtmo8</recordid><startdate>20110915</startdate><enddate>20110915</enddate><creator>Sherman, Kenneth E</creator><creator>Flamm, Steven L</creator><creator>Afdhal, Nezam H</creator><creator>Nelson, David R</creator><creator>Sulkowski, Mark S</creator><creator>Everson, Gregory T</creator><creator>Fried, Michael W</creator><creator>Adler, Michael</creator><creator>Reesink, Hendrik W</creator><creator>Martin, Marie</creator><creator>Sankoh, Abdul J</creator><creator>Adda, Nathalie</creator><creator>Kauffman, Robert S</creator><creator>George, Shelley</creator><creator>Wright, Christopher I</creator><creator>Poordad, Fred</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20110915</creationdate><title>Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection</title><author>Sherman, Kenneth E ; Flamm, Steven L ; Afdhal, Nezam H ; Nelson, David R ; Sulkowski, Mark S ; Everson, Gregory T ; Fried, Michael W ; Adler, Michael ; Reesink, Hendrik W ; Martin, Marie ; Sankoh, Abdul J ; Adda, Nathalie ; Kauffman, Robert S ; George, Shelley ; Wright, Christopher I ; Poordad, Fred</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-9db28b5f527c3ab0b045adfcdf06b2369a63cb571fda69649fef370b78702d2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anemia</topic><topic>Anemia - chemically induced</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral drugs</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Chronic infection</topic><topic>Drug Therapy, Combination</topic><topic>Exanthema - chemically induced</topic><topic>Female</topic><topic>General aspects</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oligopeptides - adverse effects</topic><topic>Oligopeptides - therapeutic use</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Recombinant Proteins</topic><topic>Ribavirin</topic><topic>Ribavirin - therapeutic use</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Technical communication</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sherman, Kenneth E</creatorcontrib><creatorcontrib>Flamm, Steven L</creatorcontrib><creatorcontrib>Afdhal, Nezam H</creatorcontrib><creatorcontrib>Nelson, David R</creatorcontrib><creatorcontrib>Sulkowski, Mark S</creatorcontrib><creatorcontrib>Everson, Gregory T</creatorcontrib><creatorcontrib>Fried, Michael W</creatorcontrib><creatorcontrib>Adler, Michael</creatorcontrib><creatorcontrib>Reesink, Hendrik W</creatorcontrib><creatorcontrib>Martin, Marie</creatorcontrib><creatorcontrib>Sankoh, Abdul J</creatorcontrib><creatorcontrib>Adda, Nathalie</creatorcontrib><creatorcontrib>Kauffman, Robert S</creatorcontrib><creatorcontrib>George, Shelley</creatorcontrib><creatorcontrib>Wright, Christopher I</creatorcontrib><creatorcontrib>Poordad, Fred</creatorcontrib><creatorcontrib>ILLUMINATE Study Team</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sherman, Kenneth E</au><au>Flamm, Steven L</au><au>Afdhal, Nezam H</au><au>Nelson, David R</au><au>Sulkowski, Mark S</au><au>Everson, Gregory T</au><au>Fried, Michael W</au><au>Adler, Michael</au><au>Reesink, Hendrik W</au><au>Martin, Marie</au><au>Sankoh, Abdul J</au><au>Adda, Nathalie</au><au>Kauffman, Robert S</au><au>George, Shelley</au><au>Wright, Christopher I</au><au>Poordad, Fred</au><aucorp>ILLUMINATE Study Team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2011-09-15</date><risdate>2011</risdate><volume>365</volume><issue>11</issue><spage>1014</spage><epage>1024</epage><pages>1014-1024</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>In patients with chronic infection with HCV genotype 1 and undetectable HCV at weeks 4 and 12 of treatment, a 24-week regimen that included telaprevir, peginterferon, and ribavirin was not inferior to a 48-week regimen.
Chronic infection with hepatitis C virus (HCV) represents a serious health issue for nearly 200 million infected persons worldwide.
1
Achievement of a sustained virologic response may be associated with improved long-term clinical outcomes, including increased survival.
2
,
3
In patients infected with HCV genotype 1, 48 weeks of treatment with peginterferon alfa and ribavirin results in a rate of sustained virologic response of 40 to 50%.
4
,
5
Telaprevir administered in combination with peginterferon and ribavirin has led to high rates of sustained virologic response in phase 2 and phase 3 trials involving patients with HCV genotype 1 infection, who have not . . .</abstract><cop>Waltham, MA</cop><pub>Massachusetts Medical Society</pub><pmid>21916639</pmid><doi>10.1056/NEJMoa1014463</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2011-09, Vol.365 (11), p.1014-1024 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3809077 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adult Aged Anemia Anemia - chemically induced Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Biological and medical sciences Biopsy Chronic infection Drug Therapy, Combination Exanthema - chemically induced Female General aspects Genotype & phenotype Genotypes Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C - drug therapy Hepatitis C - virology Human viral diseases Humans Infections Infectious diseases Interferon Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Oligopeptides - adverse effects Oligopeptides - therapeutic use Patients Pharmaceuticals Pharmacology. Drug treatments Polyethylene Glycols - therapeutic use Recombinant Proteins Ribavirin Ribavirin - therapeutic use Ribonucleic acid RNA Technical communication Viral diseases Viral hepatitis Young Adult |
| title | Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A14%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response-Guided%20Telaprevir%20Combination%20Treatment%20for%20Hepatitis%20C%20Virus%20Infection&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Sherman,%20Kenneth%20E&rft.aucorp=ILLUMINATE%20Study%20Team&rft.date=2011-09-15&rft.volume=365&rft.issue=11&rft.spage=1014&rft.epage=1024&rft.pages=1014-1024&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa1014463&rft_dat=%3Cproquest_pubme%3E2455752991%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=890081945&rft_id=info:pmid/21916639&rfr_iscdi=true |